Herminia Diana Rosas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Herminia Diana Rosas has a total of 264 co-authors. Here are the top co-authors by number of shared publications:
Steven M. Hersch
Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, United States
12 shared publicationsDavid H. Salat
7 shared publicationsFlorence Lai
Department of Neurology Massachusetts General Hospital, Harvard Medical School Charlestown Massachusetts USA
6 shared publicationsNathaniel D. Mercaldo
Department of Neurology Massachusetts General Hospital, Harvard Medical School Charlestown Massachusetts USA
6 shared publicationsAdam M. Brickman
Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Sergievsky Center, and Department of Neurology, Vagelos College of Physicians and Surgeons, Columbia University New York New York USA
5 shared publications- Florence Lai
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
5 shared publications
Latest Publications
- Open Access
Inflammation Associated With Obesity, Aging, and Amyloid Burden in Adults With Down Syndrome
Objective: Adults with Down syndrome (DS) often show elevated systemic inflammation, but the association with obesity, aging, and Alzheimer's disease (AD) pathology is not well understood. Methods: Data were drawn from 188 nondemented adults with DS participating in the Alzheimer Biomarkers Consortium‐DS (ABC‐DS). Participants completed clinical assessments, blood draws, and neuroimaging. Plasma biomarkers included indicators of general, pro‐, and anti‐inflammation. Mixed linear models tested associations between BMI, age, PET‐measured amyloid burden, and inflammatory biomarkers, adjusting for sex, trisomy type, and collection site. False discovery rate correction was applied. Results: The majority of the participants met criteria for obesity. Higher BMI was significantly associated with elevated levels of CRP, IL‐6, TNF‐α, B2M, IL‐18, and slCAM‐1 ( p < 0.05). Older age was significantly associated with higher B2M ( β = 1.22e + 05, p < 0.001). Amyloid burden was positively associated with IL‐6 ( β = 0.005, p = 0.037). Conclusions: Obesity, aging, and amyloid burden relate to systemic inflammation in adults with DS. Obesity showed the strongest and most consistent associations, emphasizing the value of regular monitoring and weight management strategies to help reduce inflammation. Aging and early amyloid accumulation showed more limited links with systemic inflammation; future work should examine whether these processes are more closely related to biomarkers of neuroinflammation as AD progresses.
Open AccessInflammation Associated With Obesity, Aging, and Amyloid Burden in Adults With Down Syndrome
Objective: Adults with Down syndrome (DS) often show elevated systemic inflammation, but the association with obesity, aging, and Alzheimer's disease (AD) pathology is not well understood. Methods: Data were drawn from 188 nondemented adults with DS participating in the Alzheimer Biomarkers Consortium‐DS (ABC‐DS). Participants completed clinical assessments, blood draws, and neuroimaging. Plasma biomarkers included indicators of general, pro‐, and anti‐inflammation. Mixed linear models tested associations between BMI, age, PET‐measured amyloid burden, and inflammatory biomarkers, adjusting for sex, trisomy type, and collection site. False discovery rate correction was applied. Results: The majority of the participants met criteria for obesity. Higher BMI was significantly associated with elevated levels of CRP, IL‐6, TNF‐α, B2M, IL‐18, and slCAM‐1 ( p < 0.05). Older age was significantly associated with higher B2M ( β = 1.22e + 05, p < 0.001). Amyloid burden was positively associated with IL‐6 ( β = 0.005, p = 0.037). Conclusions: Obesity, aging, and amyloid burden relate to systemic inflammation in adults with DS. Obesity showed the strongest and most consistent associations, emphasizing the value of regular monitoring and weight management strategies to help reduce inflammation. Aging and early amyloid accumulation showed more limited links with systemic inflammation; future work should examine whether these processes are more closely related to biomarkers of neuroinflammation as AD progresses.
- 21 May 2026
- Published by Wiley in Movement Disorders
- Vol. 41 (9) , 2444-2454
Selective Cingulum Degeneration in Huntington's Disease: A Clinically Relevant Event
Background: Huntington's disease (HD) is a neurodegenerative disorder with striatal atrophy and widespread white matter abnormalities. The cingulum bundle, central to executive and emotional functions, may be particularly vulnerable in HD. Objective: The objective of this study was to characterize cross‐sectional and longitudinal diffusion magnetic resonance imaging (MRI) changes in the cingulum bundle in HD and to determine whether these changes are clinically meaningful. Methods: This longitudinal diffusion MRI study included 66 participants (26 with HD, 20 with premanifest HD [PHD], 20 healthy control subjects) assessed at two or three time points over a mean follow‐up of 4.8 years. Multishell acquisitions were analyzed using free water elimination imaging and neurite orientation dispersion and density imaging. Values were extracted from the cingulate (CCG) and angular (CAB) subdivisions of the cingulum bundle. Group differences were assessed cross‐sectionally and longitudinally, and associations with Unified Huntington's Disease Rating Scale (UHDRS) Total Functional Capacity (TFC) were examined. Results: At baseline, HD showed widespread diffusion alterations in the CCG, whereas changes in the CAB were more limited. Longitudinally, only the CCG showed progressive change, with reduced fractional anisotropy (FAt) and neurite density index (NDI), as well as increased diffusivity and orientation dispersion. Steeper reduction of UHDRS TFC was associated with a steeper decline in NDI and FAt within the CCG. Conclusions: These findings indicate more extensive and progressive changes in the CCG than in the CAB in HD, whereas PHD showed no measurable differences. The diffusion profile suggests combined axonal loss and demyelination in fronto‐cingulate pathways and supports cingulate NDI and FAt as candidate markers of disease progression in symptomatic HD. © 2026 International Parkinson and Movement Disorder Society.
- 21 May 2026
- Published by Wiley in Movement Disorders
- Vol. 41 (9) , 2444-2454
Selective Cingulum Degeneration in Huntington's Disease: A Clinically Relevant Event
Background: Huntington's disease (HD) is a neurodegenerative disorder with striatal atrophy and widespread white matter abnormalities. The cingulum bundle, central to executive and emotional functions, may be particularly vulnerable in HD. Objective: The objective of this study was to characterize cross‐sectional and longitudinal diffusion magnetic resonance imaging (MRI) changes in the cingulum bundle in HD and to determine whether these changes are clinically meaningful. Methods: This longitudinal diffusion MRI study included 66 participants (26 with HD, 20 with premanifest HD [PHD], 20 healthy control subjects) assessed at two or three time points over a mean follow‐up of 4.8 years. Multishell acquisitions were analyzed using free water elimination imaging and neurite orientation dispersion and density imaging. Values were extracted from the cingulate (CCG) and angular (CAB) subdivisions of the cingulum bundle. Group differences were assessed cross‐sectionally and longitudinally, and associations with Unified Huntington's Disease Rating Scale (UHDRS) Total Functional Capacity (TFC) were examined. Results: At baseline, HD showed widespread diffusion alterations in the CCG, whereas changes in the CAB were more limited. Longitudinally, only the CCG showed progressive change, with reduced fractional anisotropy (FAt) and neurite density index (NDI), as well as increased diffusivity and orientation dispersion. Steeper reduction of UHDRS TFC was associated with a steeper decline in NDI and FAt within the CCG. Conclusions: These findings indicate more extensive and progressive changes in the CCG than in the CAB in HD, whereas PHD showed no measurable differences. The diffusion profile suggests combined axonal loss and demyelination in fronto‐cingulate pathways and supports cingulate NDI and FAt as candidate markers of disease progression in symptomatic HD. © 2026 International Parkinson and Movement Disorder Society.
- 1 March 2026
- Published by Wolters Kluwer Health in Neurology Open Access
- Vol. 2 (1)
A Tale of Monozygotic Twins With Down Syndrome: Divergent Clinical Paths to Dementia
Individuals with Down syndrome (DS) have a very high risk for developing Alzheimer’s disease (AD) due to the triplication of the amyloid precursor protein gene on chromosome 21. We describe a unique set of female monozygotic twins with Trisomy 21 and mild intellectual disability with significantly discordant rates of cognitive decline. The twins were followed longitudinally, starting at age 42, using cognitive assessments (Down Syndrome Mental Status Examination and Modified Cued Recall). Caregiver assessments included the Dementia Questionnaire for People with Learning Disabilities, National Task Group – Early Detection Screen for Dementia and the Neuropsychiatric Inventory. Blood was collected for AD biomarkers. Performance on baseline cognitive assessments was similar; however, by Timepoint 1, Twin 2 met criteria for mild cognitive impairment (MCI) and by Timepoint 2 met criteria for dementia due to AD. In contrast, Twin 1 remained cognitively stable. Caregiver assessment at baseline showed concerns about Twin 2’s social skills, which remained stable across timepoints. AD protein biomarker levels were similar. Discordant cognitive decline could not be explained by clinical co-morbidities, medications, or environment, suggesting that other factors, such as epigenetics, could underlie phenotypic variability and variable risk for AD in DS and deserves further study.
- 1 March 2026
- Published by Wolters Kluwer Health in Neurology Open Access
- Vol. 2 (1)
A Tale of Monozygotic Twins With Down Syndrome: Divergent Clinical Paths to Dementia
Individuals with Down syndrome (DS) have a very high risk for developing Alzheimer’s disease (AD) due to the triplication of the amyloid precursor protein gene on chromosome 21. We describe a unique set of female monozygotic twins with Trisomy 21 and mild intellectual disability with significantly discordant rates of cognitive decline. The twins were followed longitudinally, starting at age 42, using cognitive assessments (Down Syndrome Mental Status Examination and Modified Cued Recall). Caregiver assessments included the Dementia Questionnaire for People with Learning Disabilities, National Task Group – Early Detection Screen for Dementia and the Neuropsychiatric Inventory. Blood was collected for AD biomarkers. Performance on baseline cognitive assessments was similar; however, by Timepoint 1, Twin 2 met criteria for mild cognitive impairment (MCI) and by Timepoint 2 met criteria for dementia due to AD. In contrast, Twin 1 remained cognitively stable. Caregiver assessment at baseline showed concerns about Twin 2’s social skills, which remained stable across timepoints. AD protein biomarker levels were similar. Discordant cognitive decline could not be explained by clinical co-morbidities, medications, or environment, suggesting that other factors, such as epigenetics, could underlie phenotypic variability and variable risk for AD in DS and deserves further study.
- Open Access
- 9 June 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (6) , e70330
Gut dysbiosis in Down syndrome: A potentially unexplored culprit for early Alzheimer's disease
INTRODUCTION: Gut dysbiosis has been found to play a role in sporadic Alzheimer's disease (AD) but has not been explored in Down syndrome (DS), despite the strong relationship between DS and early AD. Here, we compared the gut microbiomes of 20 adults with DS, either cognitively stable or with mild cognitive impairment.METHODS: DNA from stool samples was profiled using 16S rRNA sequencing.RESULTS: Cognitive status was associated with a significant difference in overall microbiome composition (p < 0.01) and with significant differences in the abundance of Bacteroidaceae, Enterobacteriaceae, and Christensenellaceae.CONCLUSION: Just as in sporadic AD, AD in DS is associated with gut dysbiosis. Our work suggests that this is an important area for future investigation, one that may provide a novel and important target for therapeutic intervention.Highlights: Alterations in the gut microbiome are present in adults with Down syndrome (DS) with mild cognitive impairment (MCI). Increased taxa in DS‐MCI that contribute to inflammation and disrupt blood–brain barrier. Suggests a possible role of gut dysbiosis in Alzheimer's disease in adults with DS.
- 9 June 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (6) , e70330
Open AccessGut dysbiosis in Down syndrome: A potentially unexplored culprit for early Alzheimer's disease
INTRODUCTION: Gut dysbiosis has been found to play a role in sporadic Alzheimer's disease (AD) but has not been explored in Down syndrome (DS), despite the strong relationship between DS and early AD. Here, we compared the gut microbiomes of 20 adults with DS, either cognitively stable or with mild cognitive impairment.METHODS: DNA from stool samples was profiled using 16S rRNA sequencing.RESULTS: Cognitive status was associated with a significant difference in overall microbiome composition (p < 0.01) and with significant differences in the abundance of Bacteroidaceae, Enterobacteriaceae, and Christensenellaceae.CONCLUSION: Just as in sporadic AD, AD in DS is associated with gut dysbiosis. Our work suggests that this is an important area for future investigation, one that may provide a novel and important target for therapeutic intervention.Highlights: Alterations in the gut microbiome are present in adults with Down syndrome (DS) with mild cognitive impairment (MCI). Increased taxa in DS‐MCI that contribute to inflammation and disrupt blood–brain barrier. Suggests a possible role of gut dysbiosis in Alzheimer's disease in adults with DS.
- Open Access
- 5 June 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (6) , e70338
Lipoprotein(a) levels in Down syndrome: A conundrum
INTRODUCTION: Lipoprotein a (Lp(a)) is a low‐density lipoprotein (LDL)‐like particle that has been associated with risk for vascular inflammation, atherogenesis, calcification, and thrombosis in the general population but is also a risk factor for Alzheimer disease (AD).OBJECTIVE: The aim of this study was to conduct a retrospective study of lipoprotein a, Lp(a), levels in adults with Down syndrome (DS) and at risk for Alzheimer's disease (AD).METHODS: Lp(a) serum concentrations were collected from 96 adults as part of a routine clinical assessment. A comprehensive medical chart review was conducted, including clinical laboratory values that could contribute to cognitive dysfunction (e.g., thyroid function tests, C‐reactive protein(CRP), vitamin B12, lipid profiles, and vitamin D levels). Generalized linear regression models were constructed to quantify the relationship between each medical condition or laboratory value and Lp(a) level.RESULTS: There was insufficient evidence for an increased risk for earlier age of onset of AD in those with elevated Lp(a) plasma levels (≥50 mg/dL).DISCUSSION: Adults with DS may have unique neuro‐ and cardio‐ protective factors that deserve future investigation.Highlights: Lipoprotein a (Lp(a)) elevations in Down syndrome (DS) are not associated with higher risk for Alzheimer's disease (AD). Lp(a) elevations are not associated with typical vascular risk factors in DS. Distinct neuro‐ and cardio‐ protective factors may play a role in DS that may provide novel insights.
- 5 June 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (6) , e70338
Open AccessLipoprotein(a) levels in Down syndrome: A conundrum
INTRODUCTION: Lipoprotein a (Lp(a)) is a low‐density lipoprotein (LDL)‐like particle that has been associated with risk for vascular inflammation, atherogenesis, calcification, and thrombosis in the general population but is also a risk factor for Alzheimer disease (AD).OBJECTIVE: The aim of this study was to conduct a retrospective study of lipoprotein a, Lp(a), levels in adults with Down syndrome (DS) and at risk for Alzheimer's disease (AD).METHODS: Lp(a) serum concentrations were collected from 96 adults as part of a routine clinical assessment. A comprehensive medical chart review was conducted, including clinical laboratory values that could contribute to cognitive dysfunction (e.g., thyroid function tests, C‐reactive protein(CRP), vitamin B12, lipid profiles, and vitamin D levels). Generalized linear regression models were constructed to quantify the relationship between each medical condition or laboratory value and Lp(a) level.RESULTS: There was insufficient evidence for an increased risk for earlier age of onset of AD in those with elevated Lp(a) plasma levels (≥50 mg/dL).DISCUSSION: Adults with DS may have unique neuro‐ and cardio‐ protective factors that deserve future investigation.Highlights: Lipoprotein a (Lp(a)) elevations in Down syndrome (DS) are not associated with higher risk for Alzheimer's disease (AD). Lp(a) elevations are not associated with typical vascular risk factors in DS. Distinct neuro‐ and cardio‐ protective factors may play a role in DS that may provide novel insights.
- Open Access
- 1 October 2024
- Published by Wiley in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Vol. 16 (4) , e70023
Association of plasma neurofilament light chain with microstructural white matter changes in Down syndrome
INTRODUCTION: Both micro‐ and macrostructural white matter (WM) abnormalities, particularly those related to axonal degeneration, are associated with cognitive decline in adults with Down syndrome (DS) prior to a diagnosis of Alzheimer disease. Neurofilament light chain (NfL) is a support protein within myelinated axons released into blood following axonal damage. In this study we investigated cross‐sectional relationships between WM microstructural changes as measured by diffusion tensor imaging (DTI) and plasma NfL concentration in adults with DS without dementia.METHODS: Thirty cognitively stable (CS) adults with DS underwent diffusion‐weighted MRI scanning and plasma NfL measurement. DTI measures of select WM tracts were derived using automatic fiber tracking, and associations with plasma NfL were assessed using Spearman correlation coefficients.RESULTS: Higher Plasma NfL was associated with greater altered diffusion measures of select tracts.DISCUSSION: Early increases in plasma NfL may reflect early white matter microstructural changes prior to dementia in DS.Highlights: The onset of such WM changes in DS has not yet been widely studied. WM microstructural properties correlated with plasma neurofilament light chain (NfL). NfL may reflect early, selective WM changes in adults with DS at high risk of developing AD.
- 1 October 2024
- Published by Wiley in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Vol. 16 (4) , e70023
Open AccessAssociation of plasma neurofilament light chain with microstructural white matter changes in Down syndrome
INTRODUCTION: Both micro‐ and macrostructural white matter (WM) abnormalities, particularly those related to axonal degeneration, are associated with cognitive decline in adults with Down syndrome (DS) prior to a diagnosis of Alzheimer disease. Neurofilament light chain (NfL) is a support protein within myelinated axons released into blood following axonal damage. In this study we investigated cross‐sectional relationships between WM microstructural changes as measured by diffusion tensor imaging (DTI) and plasma NfL concentration in adults with DS without dementia.METHODS: Thirty cognitively stable (CS) adults with DS underwent diffusion‐weighted MRI scanning and plasma NfL measurement. DTI measures of select WM tracts were derived using automatic fiber tracking, and associations with plasma NfL were assessed using Spearman correlation coefficients.RESULTS: Higher Plasma NfL was associated with greater altered diffusion measures of select tracts.DISCUSSION: Early increases in plasma NfL may reflect early white matter microstructural changes prior to dementia in DS.Highlights: The onset of such WM changes in DS has not yet been widely studied. WM microstructural properties correlated with plasma neurofilament light chain (NfL). NfL may reflect early, selective WM changes in adults with DS at high risk of developing AD.
- Open Access
- 23 June 2023
- Published by SAGE Publications in Journal of Huntington's Disease
- Vol. 12 (2) , 163-165
To Sleep to Dream … No More? The Quest for Restorative Sleep in Huntington’s Disease, a Clinician’s Perspective
Sleep disorders are common in Huntington’s disease (HD) but are complex; their bi-directional associations with psychiatric, cognitive, and motor dysfunction makes them especially important to both consider and to treat. The author provides a perspective in brief regarding sleep disturbances in HD, based on her experience caring for, and learning from, patients with HD for more than twenty years.
- 23 June 2023
- Published by SAGE Publications in Journal of Huntington's Disease
- Vol. 12 (2) , 163-165
Open AccessTo Sleep to Dream … No More? The Quest for Restorative Sleep in Huntington’s Disease, a Clinician’s Perspective
Sleep disorders are common in Huntington’s disease (HD) but are complex; their bi-directional associations with psychiatric, cognitive, and motor dysfunction makes them especially important to both consider and to treat. The author provides a perspective in brief regarding sleep disturbances in HD, based on her experience caring for, and learning from, patients with HD for more than twenty years.
- 20 January 2023
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 109, 105289
Are you angry? Neural basis of impaired facial expression recognition in pre-manifest Huntington's
- 20 January 2023
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 109, 105289
Are you angry? Neural basis of impaired facial expression recognition in pre-manifest Huntington's
- Open Access
- 12 January 2023
- Published by Springer Nature in Research Square
Circulating miRNA Signatures in Early-Stage Huntington’s Disease
Huntington’s Disease (HD) is a neurodegenerative disorder caused by the expansion of CAG repeats on exon 1 of the huntingtin (htt) gene. This mutation results in the expression of an aberrant protein, mutant HTT, which sets in place a cascade of events that eventually leads to neuronal death within the basal ganglia and cerebral cortex. MicroRNAs (miRNAs) are a class of small non-coding RNAs of 18 - 22 nucleotides long that play important roles in post-transcriptional regulation due to their abilities to interact with the 3'-UTR regions of mRNAs. Though generated in the nucleus, a significant portion of miRNAs are secreted into the plasma as free molecules or in vesicles for intercellular signaling. Those circulating miRNAs may provide a unique opportunity to study important pathophysiological mechanisms in HD in a non-invasive manner due to their resistance to degradation, ease of detection, and their known regulatory roles in response to inflammation and neurodevelopmental disorders. More recent studies have suggested that miRNA could be used in therapeutic applications. In this study, we sought to identify the aberrant expression of specific miRNAs extracted from the plasma of early-stage HD patients. Clinical Trial Registration number: NCT01937923
- 12 January 2023
- Published by Springer Nature in Research Square
Open AccessCirculating miRNA Signatures in Early-Stage Huntington’s Disease
Huntington’s Disease (HD) is a neurodegenerative disorder caused by the expansion of CAG repeats on exon 1 of the huntingtin (htt) gene. This mutation results in the expression of an aberrant protein, mutant HTT, which sets in place a cascade of events that eventually leads to neuronal death within the basal ganglia and cerebral cortex. MicroRNAs (miRNAs) are a class of small non-coding RNAs of 18 - 22 nucleotides long that play important roles in post-transcriptional regulation due to their abilities to interact with the 3'-UTR regions of mRNAs. Though generated in the nucleus, a significant portion of miRNAs are secreted into the plasma as free molecules or in vesicles for intercellular signaling. Those circulating miRNAs may provide a unique opportunity to study important pathophysiological mechanisms in HD in a non-invasive manner due to their resistance to degradation, ease of detection, and their known regulatory roles in response to inflammation and neurodevelopmental disorders. More recent studies have suggested that miRNA could be used in therapeutic applications. In this study, we sought to identify the aberrant expression of specific miRNAs extracted from the plasma of early-stage HD patients. Clinical Trial Registration number: NCT01937923
- Open Access
- 15 July 2022
- Published by MDPI AG in Brain Sciences
- Vol. 12 (7) , 925
Correction: Hom et al. Cognitive Function during the Prodromal Stage of Alzheimer’s Disease in Down Syndrome: Comparing Models. Brain Sci. 2021, 11, 1220
We would like to submit the following correction to our recently published paper
- 15 July 2022
- Published by MDPI AG in Brain Sciences
- Vol. 12 (7) , 925
Open AccessCorrection: Hom et al. Cognitive Function during the Prodromal Stage of Alzheimer’s Disease in Down Syndrome: Comparing Models. Brain Sci. 2021, 11, 1220
We would like to submit the following correction to our recently published paper